tetano
Editor, Senior Moderator
PLoS One
. 2021 Mar 23;16(3):e0248957.
doi: 10.1371/journal.pone.0248957. eCollection 2021.
The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT
Jia-Ni Zou[SUP] 1 [/SUP], Liu Sun[SUP] 2 [/SUP], Bin-Ru Wang[SUP] 3 [/SUP], You Zou[SUP] 4 [/SUP], Shan Xu[SUP] 4 [/SUP], Yong-Jun Ding[SUP] 4 [/SUP], Li-Jun Shen[SUP] 4 [/SUP], Wen-Cai Huang[SUP] 1 [/SUP], Xiao-Jing Jiang[SUP] 5 [/SUP], Shi-Ming Chen[SUP] 4 6 [/SUP]
Affiliations
Abstract
The characteristics and evolution of pulmonary fibrosis in patients with coronavirus disease 2019 (COVID-19) have not been adequately studied. AI-assisted chest high-resolution computed tomography (HRCT) was used to investigate the proportion of COVID-19 patients with pulmonary fibrosis, the relationship between the degree of fibrosis and the clinical classification of COVID-19, the characteristics of and risk factors for pulmonary fibrosis, and the evolution of pulmonary fibrosis after discharge. The incidence of pulmonary fibrosis in patients with severe or critical COVID-19 was significantly higher than that in patients with moderate COVID-19. There were significant differences in the degree of pulmonary inflammation and the extent of the affected area among patients with mild, moderate and severe pulmonary fibrosis. The IL-6 level in the acute stage and albumin level were independent risk factors for pulmonary fibrosis. Ground-glass opacities, linear opacities, interlobular septal thickening, reticulation, honeycombing, bronchiectasis and the extent of the affected area were significantly improved 30, 60 and 90 days after discharge compared with at discharge. The more severe the clinical classification of COVID-19, the more severe the residual pulmonary fibrosis was; however, in most patients, pulmonary fibrosis was improved or even resolved within 90 days after discharge.
. 2021 Mar 23;16(3):e0248957.
doi: 10.1371/journal.pone.0248957. eCollection 2021.
The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT
Jia-Ni Zou[SUP] 1 [/SUP], Liu Sun[SUP] 2 [/SUP], Bin-Ru Wang[SUP] 3 [/SUP], You Zou[SUP] 4 [/SUP], Shan Xu[SUP] 4 [/SUP], Yong-Jun Ding[SUP] 4 [/SUP], Li-Jun Shen[SUP] 4 [/SUP], Wen-Cai Huang[SUP] 1 [/SUP], Xiao-Jing Jiang[SUP] 5 [/SUP], Shi-Ming Chen[SUP] 4 6 [/SUP]
Affiliations
- PMID: 33755708
- DOI: 10.1371/journal.pone.0248957
Abstract
The characteristics and evolution of pulmonary fibrosis in patients with coronavirus disease 2019 (COVID-19) have not been adequately studied. AI-assisted chest high-resolution computed tomography (HRCT) was used to investigate the proportion of COVID-19 patients with pulmonary fibrosis, the relationship between the degree of fibrosis and the clinical classification of COVID-19, the characteristics of and risk factors for pulmonary fibrosis, and the evolution of pulmonary fibrosis after discharge. The incidence of pulmonary fibrosis in patients with severe or critical COVID-19 was significantly higher than that in patients with moderate COVID-19. There were significant differences in the degree of pulmonary inflammation and the extent of the affected area among patients with mild, moderate and severe pulmonary fibrosis. The IL-6 level in the acute stage and albumin level were independent risk factors for pulmonary fibrosis. Ground-glass opacities, linear opacities, interlobular septal thickening, reticulation, honeycombing, bronchiectasis and the extent of the affected area were significantly improved 30, 60 and 90 days after discharge compared with at discharge. The more severe the clinical classification of COVID-19, the more severe the residual pulmonary fibrosis was; however, in most patients, pulmonary fibrosis was improved or even resolved within 90 days after discharge.